Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-IMD registry analysis of standard clinical care in ARG1 deficiency with focus on Loargys
NL-OMON58219Not yet recruiting
- Sponsor
- Immedica
- Start
- Feb 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegzilarginase in arginase 1 deficiency (ARG1-D), sponsored by Immedica. Primary endpoint: Durability of treatment response. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
pegzilarginase
03
Conditions
arginase 1 deficiency (ARG1-D)
Beyond the preview
Go deeper on NL-OMON58219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58219.